Skip to main content

REVIEW article

Front. Med.
Sec. Nuclear Medicine
Volume 11 - 2024 | doi: 10.3389/fmed.2024.1515040
This article is part of the Research Topic Expert Opinions & Viewpoints in Nuclear Medicine View all articles

SEMIQUANTITATIVE 2-[ 18 F]FDG PET/CT-BASED PARAMETERS ROLE IN LYMPHOMA

Provisionally accepted
Domenico Albano Domenico Albano 1*Marco Ravanelli Marco Ravanelli 1Rexhep Durmo Rexhep Durmo 2Annibale Versari Annibale Versari 2Angelina Filice Angelina Filice 3Alessio Rizzo Alessio Rizzo 4Manuela Racca Manuela Racca 4Daniele Antonio Pizzuto Daniele Antonio Pizzuto 5Francesco Bertagna Francesco Bertagna 1Salvatore Annunziata Salvatore Annunziata 5
  • 1 University of Brescia, Brescia, Italy
  • 2 University of Modena and Reggio Emilia, Modena, Emilia-Romagna, Italy
  • 3 IRCCS Local Health Authority of Reggio Emilia, Reggio Emilia, Italy
  • 4 IRCCS Candiolo Cancer Institute, Turin, Piedmont, Italy
  • 5 Agostino Gemelli University Policlinic, Rome, Lazio, Italy

The final, formatted version of the article will be published soon.

    2-deoxy-2-[18F]-fluoro-D-glucose (2-[ 18 F]FDG) positron emission tomography/computed tomography (PET/CT) plays a crucial role in the management of lymphoma in different settings, such as staging disease, assessing response to therapy, predicting prognosis, and planning RT. Beside visual analysis, several semiquantitative parameters were introduced to study lymphoma with promising results. These parameters can represent different disease characteristics, like body composition (such as sarcopenic index), dissemination of disease (Dmax), tumor burden (including metabolic tumor volume) and texture features. All these parameters showed promising results, especially in terms of prognosis (progression free survival and overall survival), but lack of standardization and shared methodology remains a big issue. Further improvements in PET-based biomarkers are imminent, although their incorporation into clinical decision-making currently has methodological shortcomings that need to be addressed with confirmatory prospective validation in selected patient populations. This narrative review focuses on the studies that showed the prognostic and predictive role of these semiquantitative parameters in lymphoma, addressing also their potential utility in the clinical practice.

    Keywords: PET/CT, Lymphoma, FDG, Sarcopenia, MTV, TLG, Dmax, Radiomics

    Received: 22 Oct 2024; Accepted: 04 Dec 2024.

    Copyright: © 2024 Albano, Ravanelli, Durmo, Versari, Filice, Rizzo, Racca, Pizzuto, Bertagna and Annunziata. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Domenico Albano, University of Brescia, Brescia, Italy

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.